115 related articles for article (PubMed ID: 3615349)
21. Application of principles of steady-state kinetics to the estimation of gamma-aminobutyric acid turnover rate in nuclei of rat brain.
Bertilsson L; Mao CC; Costa E
J Pharmacol Exp Ther; 1977 Feb; 200(2):277-84. PubMed ID: 839439
[TBL] [Abstract][Full Text] [Related]
22. Release of gamma-[3H]aminobutyric acid from rat olfactory bulb and substantia nigra: differential modulation by glutamic acid.
Jaffé EH; Vaello ML
J Neurochem; 1989 Jun; 52(6):1766-74. PubMed ID: 2566648
[TBL] [Abstract][Full Text] [Related]
23. Changes in GABA content and turnover in discrete regions of rat brain after systemic administration of caerulein.
Nakamura K; Matsumoto T; Hirano M; Uchimura H
Psychopharmacology (Berl); 1990; 101(1):73-6. PubMed ID: 2343075
[TBL] [Abstract][Full Text] [Related]
24. Susceptibility to seizures produced by pilocarpine in rats after microinjection of isoniazid or gamma-vinyl-GABA into the substantia nigra.
Turski L; Cavalheiro EA; Schwarz M; Turski WA; De Moraes Mello LE; Bortolotto ZA; Klockgether T; Sontag KH
Brain Res; 1986 Apr; 370(2):294-309. PubMed ID: 3708328
[TBL] [Abstract][Full Text] [Related]
25. Characterization of extracellular GABA in the substantia nigra reticulata by means of brain microdialysis.
Timmerman W; Zwaveling J; Westerink BH
Naunyn Schmiedebergs Arch Pharmacol; 1992 Jun; 345(6):661-5. PubMed ID: 1635589
[TBL] [Abstract][Full Text] [Related]
26. Modulation of methylenedioxymethamphetamine-induced striatal dopamine release by the interaction between serotonin and gamma-aminobutyric acid in the substantia nigra.
Yamamoto BK; Nash JF; Gudelsky GA
J Pharmacol Exp Ther; 1995 Jun; 273(3):1063-70. PubMed ID: 7791076
[TBL] [Abstract][Full Text] [Related]
27. Bilobalide prevents reduction of gamma-aminobutyric acid levels and glutamic acid decarboxylase activity induced by 4-O-methylpyridoxine in mouse hippocampus.
Sasaki K; Hatta S; Wada K; Ohshika H; Haga M
Life Sci; 2000 Jun; 67(6):709-15. PubMed ID: 12659176
[TBL] [Abstract][Full Text] [Related]
28. Seizure protection and increased nerve-terminal GABA: delayed effects of GABA transaminase inhibition.
Gale K; Iadarola MJ
Science; 1980 Apr; 208(4441):288-91. PubMed ID: 6768130
[TBL] [Abstract][Full Text] [Related]
29. Estradiol benzoate decreases nigral GABAergic activity in male rats.
Nicoletti F; Meek JL
Brain Res; 1985 Apr; 332(1):179-83. PubMed ID: 2986760
[TBL] [Abstract][Full Text] [Related]
30. GABAergic afferents activate both GABAA and GABAB receptors in mouse substantia nigra dopaminergic neurons in vivo.
Brazhnik E; Shah F; Tepper JM
J Neurosci; 2008 Oct; 28(41):10386-98. PubMed ID: 18842898
[TBL] [Abstract][Full Text] [Related]
31. Use of inhibitors of gamma-aminobutyric acid (GABA) transaminase for the estimation of GABA turnover in various brain regions of rats: a reevaluation of aminooxyacetic acid.
Löscher W; Hönack D; Gramer M
J Neurochem; 1989 Dec; 53(6):1737-50. PubMed ID: 2809589
[TBL] [Abstract][Full Text] [Related]
32. Inhibitors of GABA metabolism: implications for Huntington's disease.
Schwarcz R; Bennett JP; Coyle JT
Ann Neurol; 1977 Oct; 2(4):299-303. PubMed ID: 152600
[TBL] [Abstract][Full Text] [Related]
33. Anticonvulsant and proconvulsant effects of inhibitors of GABA degradation in the amygdala-kindling model.
Löscher W; Jäckel R; Müller F
Eur J Pharmacol; 1989 Apr; 163(1):1-14. PubMed ID: 2744084
[TBL] [Abstract][Full Text] [Related]
34. Rotational behaviour following inhibition of GABA metabolism unilaterally in the rat substantia nigra.
Dray ; Oakley NR; Simmonds MA
J Pharm Pharmacol; 1975 Aug; 27(8):627-9. PubMed ID: 239186
[No Abstract] [Full Text] [Related]
35. Muscarinic antagonists in substantia nigra influence the decarboxylation of L-dopa in striatum.
Izurieta-Sánchez P; Sarre S; Ebinger G; Michotte Y
Eur J Pharmacol; 2000 Jul; 399(2-3):151-60. PubMed ID: 10884514
[TBL] [Abstract][Full Text] [Related]
36. In vivo vulnerability of dopamine neurons to inhibition of energy metabolism.
Zeevalk GD; Manzino L; Hoppe J; Sonsalla P
Eur J Pharmacol; 1997 Feb; 320(2-3):111-9. PubMed ID: 9059843
[TBL] [Abstract][Full Text] [Related]
37. GABAergic nerve terminals decrease in the substantia nigra following hemitransections of the striatonigral and pallidonigral pathways.
Ribak CE; Vaughn JE; Roberts E
Brain Res; 1980 Jun; 192(2):413-20. PubMed ID: 7378797
[TBL] [Abstract][Full Text] [Related]
38. Effects of acute and subacute treatment with ergot drugs on the GABA system in specific brain regions.
Pericić D
J Pharm Pharmacol; 1981 Oct; 33(10):655-9. PubMed ID: 6117619
[TBL] [Abstract][Full Text] [Related]
39. Effects of GABA and L-glutamic acid on the potassium-evoked in vitro release of substance P- and neurokinin A-like immunoreactivities are different in the rat striatum and substantia nigra.
Humpel C; Saria A
Neurosci Lett; 1989 Oct; 105(1-2):159-63. PubMed ID: 2484728
[TBL] [Abstract][Full Text] [Related]
40. Effects of the unilateral striatal lesion on neurotransmitter markers in the contralateral striatum and both substantia nigrae of the rat.
Masuo Y; Kanazawa I
Neuroscience; 1988 Dec; 27(3):827-36. PubMed ID: 2908058
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
